| P2093 | author name string | Sanjiv J Shah | |
| | Ravi B Patel | |
| P2860 | cites work | Visceral Adipose Tissue Drives Cardiac Aging Through Modulation of Fibroblast Senescence by Osteopontin Production. | Q51745075 |
| | Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. | Q52900479 |
| | Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. | Q53532447 |
| | Effects of Milrinone on Rest and Exercise Hemodynamics in Heart Failure With Preserved Ejection Fraction. | Q54406123 |
| | Prognostic importance of pathophysiologic markers in patients with heart failure and preserved ejection fraction. | Q54960430 |
| | Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD) | Q59192167 |
| | Cardiomyocyte Stiffness in Diastolic Heart Failure | Q62476659 |
| | Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension | Q70533705 |
| | Sodium Nitrite Improves Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction | Q86421869 |
| | Heart failure: Macrophages promote cardiac fibrosis and diastolic dysfunction | Q87919221 |
| | Heart failure: Histone deacetylases and diastolic dysfunction | Q87919223 |
| | Distinct Myocardial Targets for Diabetes Therapy in Heart Failure With Preserved or Reduced Ejection Fraction | Q89748582 |
| | Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease | Q24323316 |
| | Is enhancing cGMP-PKG signalling a promising therapeutic target for heart failure with preserved ejection fraction? | Q26765931 |
| | A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation | Q26850196 |
| | The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction | Q27024279 |
| | The case for inhibiting p38 mitogen-activated protein kinase in heart failure | Q28080674 |
| | Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral? | Q28088503 |
| | Angiotensin-neprilysin inhibition versus enalapril in heart failure | Q28247091 |
| | Trends in prevalence and outcome of heart failure with preserved ejection fraction | Q28252937 |
| | Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus | Q28297680 |
| | The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. | Q30358659 |
| | Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study | Q33589713 |
| | TNF-alpha induces TGF-beta1 expression in lung fibroblasts at the transcriptional level via AP-1 activation | Q33793939 |
| | Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury | Q33873592 |
| | FGF23 induces left ventricular hypertrophy | Q34028891 |
| | Murine Models of Heart Failure with Preserved Ejection Fraction: a "Fishing Expedition". | Q49203906 |
| | Global Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated with Heart Failure and Preserved or Reduced Ejection Fraction. | Q49791521 |
| | Histone deacetylase activity governs diastolic dysfunction through a nongenomic mechanism. | Q50045909 |
| | Visceral Congestion in Heart Failure: Right Ventricular Dysfunction, Splanchnic Hemodynamics, and the Intestinal Microenvironment | Q50093822 |
| | Metformin and thiazolidinedione use in Medicare patients with heart failure | Q34210642 |
| | Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis | Q34316944 |
| | Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans. | Q34409745 |
| | Spironolactone for heart failure with preserved ejection fraction | Q34414462 |
| | Advanced glycation end products: sparking the development of diabetic vascular injury | Q34555042 |
| | Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis | Q34625372 |
| | Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Q34673134 |
| | Interleukin-16 promotes cardiac fibrosis and myocardial stiffening in heart failure with preserved ejection fraction | Q34873552 |
| | Irbesartan in patients with heart failure and preserved ejection fraction | Q34877640 |
| | Phenomapping for novel classification of heart failure with preserved ejection fraction | Q34995857 |
| | Right heart dysfunction in heart failure with preserved ejection fraction | Q35588220 |
| | Disruption of ATP-binding cassette B8 in mice leads to cardiomyopathy through a decrease in mitochondrial iron export | Q35837234 |
| | Heart Failure With Preserved Ejection Fraction Induces Beiging in Adipose Tissue | Q35882942 |
| | Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD. | Q36104887 |
| | Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction | Q36459987 |
| | Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure | Q36550830 |
| | The Failing Heart Relies on Ketone Bodies as a Fuel | Q36614537 |
| | Discovery of novel PDE9 inhibitors capable of inhibiting Aβ aggregation as potential candidates for the treatment of Alzheimer's disease | Q36615734 |
| | Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives | Q36682182 |
| | Overview of PDEs and their regulation | Q36739122 |
| | Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study) | Q36985609 |
| | Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. | Q37058596 |
| | Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial | Q37328507 |
| | Coassembly of Mgm1 isoforms requires cardiolipin and mediates mitochondrial inner membrane fusion | Q37365417 |
| | Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis | Q37580301 |
| | Expert consensus document: Mitochondrial function as a therapeutic target in heart failure | Q37699474 |
| | Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction. | Q38110226 |
| | Gigantic business: titin properties and function through thick and thin | Q38195698 |
| | The pathophysiology of heart failure with preserved ejection fraction. | Q38222648 |
| | Targeting interleukin-1 in heart failure and inflammatory heart disease | Q38260179 |
| | INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved Ejection Fraction): Rationale and Design | Q38377133 |
| | Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial | Q38389314 |
| | Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial | Q38394069 |
| | Enhanced pulmonary vasodilator reserve and abnormal right ventricular: pulmonary artery coupling in heart failure with preserved ejection fraction | Q38413616 |
| | Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. | Q38420677 |
| | Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study | Q38488882 |
| | Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease | Q38606033 |
| | Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review | Q38658569 |
| | Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT. | Q38667037 |
| | Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure | Q38678461 |
| | Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction | Q38691846 |
| | Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation | Q38727741 |
| | Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes | Q38729780 |
| | Atrial fibrillation in heart failure with preserved ejection fraction: Insights into mechanisms and therapeutics | Q38806909 |
| | Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus | Q38827756 |
| | A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. | Q38872061 |
| | Partial Adenosine A1 Agonist in Heart Failure | Q38988016 |
| | Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial | Q39405472 |
| | Cardiosphere-derived cells reverse heart failure with preserved ejection fraction (HFpEF) in rats by decreasing fibrosis and inflammation | Q40286144 |
| | Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil | Q41242943 |
| | Levosimendan improves calcium sensitivity of diaphragm muscle fibres from a rat model of heart failure | Q41874182 |
| | Skeletal Muscle Mitochondrial Content, Oxidative Capacity, and Mfn2 Expression Are Reduced in Older Patients With Heart Failure and Preserved Ejection Fraction and Are Related to Exercise Intolerance | Q42062803 |
| | Experimentally Increasing the Compliance of Titin Through RNA Binding Motif-20 (RBM20) Inhibition Improves Diastolic Function In a Mouse Model of Heart Failure With Preserved Ejection Fraction. | Q42382004 |
| | PDE2-mediated cAMP hydrolysis accelerates cardiac fibroblast to myofibroblast conversion and is antagonized by exogenous activation of cGMP signaling pathways. | Q42454314 |
| | Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation | Q42752870 |
| | Adenosine A1 receptor activation reduces opening of mitochondrial permeability transition pores in hypoxic cardiomyocytes | Q43269097 |
| | Getting to the "Heart" of Cardiac Disease by Decreasing Mitochondrial Iron. | Q43288665 |
| | Anti-aldosteronergic effect of torasemide | Q44265911 |
| | Molecular mechanism of levosimendan action: an update | Q44580510 |
| | Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial | Q44588075 |
| | RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study | Q44596273 |
| | Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2). | Q45058507 |
| | Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. | Q45921765 |
| | Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview. | Q45947184 |
| | Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Tria | Q45999393 |
| | Hypophosphorylation of the Stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. | Q46140653 |
| | Levosimendan enhances force generation of diaphragm muscle from patients with chronic obstructive pulmonary disease | Q46259496 |
| | Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure | Q46556129 |
| | Excess PTH in CRF induces pulmonary calcification, pulmonary hypertension and right ventricular hypertrophy | Q46850755 |
| | Osteopontin expression is required for myofibroblast differentiation | Q46850865 |
| | Functional and structural alterations of cardiac and skeletal muscle mitochondria in heart failure patients | Q46915783 |
| | Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials | Q47614541 |
| | Inflammation in Heart Failure With Preserved Ejection Fraction: Time to Put Out the Fire | Q47716060 |
| | Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction | Q47755913 |
| | Cardiac macrophages promote diastolic dysfunction. | Q48232420 |
| | The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial | Q48395213 |
| | Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. | Q48414650 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heart failure | Q181754 |
| | ejection fraction | Q641303 |
| | Heart failure with preserved ejection fraction | Q3799239 |
| P304 | page(s) | 41-63 | |
| P577 | publication date | 2018-10-08 | |
| P1433 | published in | Annual Review of Pharmacology and Toxicology | Q567365 |
| P1476 | title | Drug Targets for Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach and Review of Contemporary Clinical Trials | |
| P478 | volume | 59 | |